Data from the phase 3 study confirmed the lot consistency, immunogenicity, safety, and tolerability of a toxoid-based Clostridioides difficile vaccine. Neutralizing antibody responses 1 month after ...

Scientists have made a breakthrough in the hunt for a new vaccine for killer hospital bug Clostridioides difficile (C. diff). Scientists have made a breakthrough in the hunt for a new vaccine for ...

Intestinal stem cells help regenerate the lining of the intestine, and that lining or epithelium plays a number of critical roles in digestion, nutrient absorption, and immunity. Scientists have now ...

Gastrointestinal tumors remain a global health challenge, with high incidence and mortality. Among them, colorectal cancer (CRC) carries the heaviest burden and serves as a key model for how the gut ...

A study funded by the National Institutes of Health found that Glucosyltransferase domain is a possible molecular target for therapeutic interventions for Clostridioides difficile infection.

A novel vaccination approach developed by Vanderbilt Health researchers cleared the harmful gut bacterium Clostridioides ...

A new review looks at the challenges of testing for Clostridioides (Clostridium) difficile infection (CDI) and recommendations for newer diagnostic tests. Accurate diagnosis of CDI is critical for ...

Clostridium bacteria, computer illustration. Clostridia are spore-forming bacteria that include several human pathogenic species, C. difficile, C. tetani, C. botulinum, C. perfringens, and others. C.

A University of California, Irvine-led study suggests that the glucosyltransferase domain (GTD) is an ideal molecular target for therapeutic interventions for Clostridioides difficile infection (CDI).

Scientists have made a breakthrough in the hunt for a new vaccine for killer hospital bug Clostridioides difficile (C. diff). University of Exeter researchers first identified a gene in C. diff ...